ARCHIVES

LAK/IL-2 Extramural Trials Expanded to 20 More cancers

This article is from The Cancer Letter archive.

Vol. 14 No. 02 | January 8, 1988

Download PDF Visit The Full Archive

Related Articles

Risk-Benefit Analysis Advised Prior To Hormone Therapy

August 27, 2010

ACS To Implement Cancer Response Systems Nationwide

August 2, 1985

NCI Reports On Efforts To Prevent Cancer In Native Americans

August 13, 1999

Degarelix Active In Phase II Trial In Prostate Cancer

October 29, 2004

NCCTG Plans To Conduct Phase II Study Of Brostallicin Plus Cisplatin For mTNBC

April 30, 2010

NCI’s Frei & Freireich era Lauded As Researchers Receive First NIH Distinguished Alumni Award

September 14, 1990